- Home
- GNPX vs EONR Comparison
GNPX vs EONR Comparison
Compare GNPX & EONR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- EONR
- Stock Information
- Founded
- GNPX 2009
- EONR 2017
- Country
- GNPX United States
- EONR United States
- Employees
- GNPX N/A
- EONR N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- EONR
- Sector
- GNPX Health Care
- EONR
- Exchange
- GNPX Nasdaq
- EONR NYSE
- Market Cap
- GNPX 6.6M
- EONR 6.8M
- IPO Year
- GNPX 2018
- EONR N/A
- Fundamental
- Price
- GNPX $0.28
- EONR $0.38
- Analyst Decision
- GNPX
- EONR Strong Buy
- Analyst Count
- GNPX 0
- EONR 1
- Target Price
- GNPX N/A
- EONR $2.00
- AVG Volume (30 Days)
- GNPX 3.4M
- EONR 14.9M
- Earning Date
- GNPX 08-08-2025
- EONR 08-15-2025
- Dividend Yield
- GNPX N/A
- EONR N/A
- EPS Growth
- GNPX N/A
- EONR N/A
- EPS
- GNPX N/A
- EONR N/A
- Revenue
- GNPX N/A
- EONR $19,638,616.00
- Revenue This Year
- GNPX N/A
- EONR $46.94
- Revenue Next Year
- GNPX N/A
- EONR $64.38
- P/E Ratio
- GNPX N/A
- EONR N/A
- Revenue Growth
- GNPX N/A
- EONR N/A
- 52 Week Low
- GNPX $0.20
- EONR $0.33
- 52 Week High
- GNPX $3.97
- EONR $2.92
- Technical
- Relative Strength Index (RSI)
- GNPX 55.29
- EONR N/A
- Support Level
- GNPX $0.25
- EONR N/A
- Resistance Level
- GNPX $0.27
- EONR N/A
- Average True Range (ATR)
- GNPX 0.03
- EONR 0.00
- MACD
- GNPX 0.00
- EONR 0.00
- Stochastic Oscillator
- GNPX 90.71
- EONR 0.00
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About EONR EON RESOURCES INC
EON Resources Inc is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. Its current focus is as an upstream energy company producing oil and gas properties in the Permian Basin.